再鼎医药_JPM_20240108.pdf

1、1Building a Global Biopharma LeaderJP Morgan 42nd Annual Healthcare ConferenceJanuary 8,20242Forward-Looking StatementsThis presentation contains forward-looking statements relating to our strategy and plans;potential of and expectations for our business and pipeline programs;our goals and expectati

2、ons under our growth strategy(including our expectations regarding our commercial-stage products,clinical-stage global-right products,revenue growth/CAGR,operating margins,and cash flow);the peak sales potential of our programs;capital allocation and investment strategy;clinical development programs

3、 and related clinical trials;clinical trial data,data readouts,and presentations;risks and uncertainties associated with drug development and commercialization;regulatory discussions,submissions,filings,and approvals and the timing thereof;the potential benefits,safety,and efficacy of our products a

4、nd product candidates and those of our collaboration partners;the expected benefits and potential of investments,collaborations,and business development activities;our future financial and operating results;and financial guidance.All statements,other than statements of historical fact,included in th

5、is presentation are forward-looking statements,and can be identified by words such as“aim,”“anticipate,”“believe,”“could,”“estimate,”“expect,”“forecast,”“goal,”“intend,”“may,”“plan,”“possible,”“potential,”“will,”“would,”and other similar expressions.Such statements constitute forward-looking stateme

6、nts within the meaning of the Private Securities Litigation Reform Act of 1995.Forward-looking statements are not guarantees or assurances of future performance.Forward-looking statements are based on our expectations and assumptions as of the date of this presentation and are subject to inherent un